American Journal of Clinical Dermatology

, Volume 12, Issue 3, pp 171–180 | Cite as

A Systematic Approach to Systemic Contact Dermatitis and Symmetric Drug-Related Intertriginous and Flexural Exanthema (SDRIFE)

A Closer Look at These Conditions and an Approach to Intertriginous Eruptions
Review Article Systematic Approach to Systemic Contact Dermatitis and SDRIFE

Abstract

Systemic contact dermatitis is a condition that occurs when an individual sensitized to a contact allergen is exposed to that same allergen or a cross-reacting molecule through a systemic route. Systemic exposure to allergens can include transcutaneous, transmucosal, oral, intravenous, intramuscular, and inhalational routes. Baboon syndrome is perhaps the most recognizable form of systemic contact dermatitis, presenting with diffuse, well demarcated erythema of the buttocks, upper inner thighs, and axillae. Other forms of systemic contact dermatitis include dermatitis at sites of previous exposure to the allergen such as at a previous site of dermatitis or at sites of previous positive patch tests, dyshidrotic hand eczema, flexural dermatitis, exanthematous rash, erythroderma, and vasculitis-like lesions.

The most common causes of systemic contact dermatitis consist of three groups of allergens: (i) metals including mercury, nickel, and gold; (ii) medications including aminoglycoside antibacterials, corticosteroids, and aminophylline; and (iii) plants and herbal products including the Compositae and Anacardiaceae plant families and Balsam of Peru.

Baboon syndrome caused by systemic medications without a known history of previous cutaneous sensitization in the patient has been termed drug-related baboon syndrome (DRBS) or symmetric drug-related intertriginous and flexural exanthema (SDRIFE). Criteria for SDRIFE include exposure to systemic drug at first or repeated dose, erythema of the gluteal/perianal area and/or V-shaped erythema of the inguinal area, involvement of at least one other intertriginous localization, symmetry of affected areas, and absence of systemic toxicity. The most common causes are aminopenicillins, β-lactam antibacterials, and certain chemotherapeutic agents, though the list of etiologic agents continues to grow. Baboon syndrome and SDRIFE should be strongly considered in a patient presenting with a symmetric intertriginous eruption involving multiple body folds. With the knowledge of the most frequent causes of these conditions, a detailed history and review of exposures will guide the clinician in the search for the most likely etiologic agent.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nielsen NH, Linneberg A, Menne T, et al. Allergic contact sensitization in an adult Danish population: two cross-sectional surveys eight years apart (the Copenhagen Allergy Study). Acta Derm Venereol 2001 Jan-Feb; 81 (1): 31–4Google Scholar
  2. 2.
    Hausermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis 2004 Nov-Dec; 51 (5-6): 297–310Google Scholar
  3. 3.
    Veien NK, Menne T. Systemic contact dermatitis. In: Frosch PJ, Menne T, Lepoittevin JP, editors. Contact dermatitis. 4th ed. Berlin: Springer, 2006: 295–305CrossRefGoogle Scholar
  4. 4.
    Menne T, Veien NK, Maibach HL. Systemic contact dermatitis. Am J Contact Dermatitis 1994; 5: 1–12Google Scholar
  5. 5.
    Jacob SE, Zapolanski T. Systemic contact dermatitis. Dermatitis 2008 Jan-Feb; 19 (1): 9–15Google Scholar
  6. 6.
    Shelley WB, Crissey JT. Thomas Bateman. In: Shelley WB, Crissey JT, editors. Classics in clinical dermatology. Springfield (IL): Charles C. Thomas, 1970: 22Google Scholar
  7. 7.
    Nakayama H, Niki F, Shono M, et al. Mercury exanthema. Contact Dermatitis 1983; 9: 411–7PubMedCrossRefGoogle Scholar
  8. 8.
    Andersen KE, Hjorth N, Menne T. The baboon syndrome: systemicallyinduced allergic contact dermatitis. Contact Dermatitis 1984; 10: 97–100PubMedCrossRefGoogle Scholar
  9. 9.
    Torchia D, Capretti C, Pizzo B, et al. Patch test triggering recurrence of distant dermatitis: the flare-up phenomenon. CMAJ 2008 Aug 12; 179 (4): 341Google Scholar
  10. 10.
    Moreno-Ramírez D, García-Bravo B, Pichardo AR, et al. Baboon syndrome in childhood: easy to avoid, easy to diagnose, but the problem continues. Pediatr Dermatol 2004 May-Jun; 21 (3): 250–3Google Scholar
  11. 11.
    Ozkaya E, Mirzoyeva L, Otkur B. Mercury-induced systemic allergic dermatitis caused by ‘white precipitate’ in a skin lightening cream. Contact Dermatitis 2009; 60: 61–3PubMedCrossRefGoogle Scholar
  12. 12.
    Dou X, Liu LL, Zhu XJ. Nickel-elicited systemic contact dermatitis. Contact Dermatitis 2003 Mar; 48 (3): 126–9Google Scholar
  13. 13.
    Nielsen GD, Jepsen LV, Jorgensen PJ. Nickel-sensitive patients with vesicular hand eczema: oral challenge with a diet naturally high in nickel. Br J Dermatol 1990 Mar; 122 (3): 299–308Google Scholar
  14. 14.
    Pigatto PD, Guzzi G. Systemic contact dermatitis from nickel associated with orthodontic appliances. Contact Dermatitis 2004 Feb; 50 (2): 100–1Google Scholar
  15. 15.
    Raison-Peyron N, Guillard O, Khalil Z, et al. Nickel-elicited systemic contact dermatitis from a peripheral intravenous catheter. Contact Dermatitis 2005 Oct; 53 (4): 222–5Google Scholar
  16. 16.
    Raison-Peyron N, Kluger N, Guillard O, et al. A new case of systemic contact eczema to nickel in a peripheral venous catheter. Ann Dermatol Venereol 2008 Nov; 135 (11): 769–72Google Scholar
  17. 17.
    Nosbaum A, Rival-Tringali AL, Barth X, et al. Nickel-induced systemic allergic dermatitis from a sacral neurostimulator. Contact Dermatitis 2008 Nov; 59 (5): 319–20Google Scholar
  18. 18.
    Gimenez-Arnau A, Riambau V, Serra-Baldrich E. Metal-induced generalized pruriginous dermatitis and endovascular surgery. Contact Dermatitis 2000 Jul; 43 (1): 35–40Google Scholar
  19. 19.
    Lofgren SM, Warshaw EM. Dyshidrosis: epidemiology, clinical characteristics, and therapy. Dermatitis 2006 Dec; 17 (4): 165–81Google Scholar
  20. 20.
    Veien NK, Hattel T, Justesen O, et al. Dietary treatment of nickel dermatitis. Acta Derm Venereol 1985; 65 (2): 138–42PubMedGoogle Scholar
  21. 21.
    Veien NK, Hattel T, Laurberg G. Low nickel diet: an open, prospective trial. J Am Acad Dermatol 1993 Dec; 29 (6): 1002–7Google Scholar
  22. 22.
    Guin JD, Phillips D. Erythroderma from systemic contact dermatitis: a complication of systemic gentamicin in a patient with contact allergy to neomycin. Cutis 1989 Jun; 43 (6): 564–7Google Scholar
  23. 23.
    Quirce S, Alvarez MJ, Olaguibel JM, et al. Systemic contact dermatitis from oral prednisone. Contact Dermatitis 1994 Jan; 30 (1): 53–4Google Scholar
  24. 24.
    Chew AL, Maibach HI. Multiple corticosteroid orally elicited allergic contact dermatitis in a patient with multiple topical corticosteroid allergic contact dermatitis. Cutis 2000 May; 65 (5): 307–11Google Scholar
  25. 25.
    Poon E, Fewings JM. Generalized eczematous reaction to budesonide in a nasal spray with cross-reactivity to triamcinolone. Australas J Dermatol 2001 Feb; 42 (1): 36–7Google Scholar
  26. 26.
    Nucera E, Buonomo A, Pollastrini E, et al. A case of cutaneous delayed-type allergy to oral dexamethasone and to betamethasone. Dermatology 2002; 204 (3): 248–50PubMedCrossRefGoogle Scholar
  27. 27.
    Walker SL, Ferguson JE. Systemic allergic contact dermatitis due to ethylenediamine following administration of oral aminophylline. Br J Dermatol 2004 Mar; 150 (3): 594Google Scholar
  28. 28.
    Isaksson M, Ljunggren B. Systemic contact dermatitis from ethylenediamine in an aminophylline preparation presenting as the baboon syndrome. Acta Derm Venereol 2003; 83 (1): 69–70PubMedCrossRefGoogle Scholar
  29. 29.
    De Castro Martinez FJ, Ruiz FJ, Tornero P, et al. Systemic contact dermatitis due to fusidic acid. Contact Dermatitis 2006 Mar; 54 (3): 169Google Scholar
  30. 30.
    Corazza M, Mantovani L, Montanari A, et al. Allergic contact dermatitis from transdermal estradiol and systemic contact dermatitis from oral estradiol: a case report. J Reprod Med 2002 Jun; 47 (6): 507–9Google Scholar
  31. 31.
    Gallo R, Parodi A. Baboon syndrome from 5-aminosalicylic acid. Contact Dermatitis 2002 Feb; 46 (2): 110Google Scholar
  32. 32.
    Tamagawa-Mineoka R, Katoh N, Yoneda K, et al. Systemic allergic contact dermatitis due to phenylephrine in eyedrops, with a long-lasting allergic patch test reaction. Eur J Dermatol 2010 Jan-Feb; 20 (1): 125–6Google Scholar
  33. 33.
    Sasseville D. Clinical patterns of pytodermatitis. Dermatol Clin 2009 Jul; 27 (3): 299–308Google Scholar
  34. 34.
    Rodríguez-Serna M, Sanchez-Motilla JM, Ramon R, et al. Allergic and systemic contact dermatitis from Matricaria chamomilla tea. Contact Dermatitis 1998 Oct; 39 (4): 192–3Google Scholar
  35. 35.
    Mahajan VK, Sharma NL, Sharma RC. Parthenium dermatitis: is it a systemic contact dermatitis or an airborne contact dermatitis? Contact Dermatitis 2004 Nov-Dec; 51 (5-6): 231–4Google Scholar
  36. 36.
    Oh SH, Haw CR, Lee MH. Clinical and immunologic features of systemic contact dermatitis from ingestion of Rhus (Toxicodendron). Contact Dermatitis 2003 May; 48 (5): 251–4Google Scholar
  37. 37.
    Cardinali C, Francalanci S, Giomi B, et al. Systemic contact dermatitis from herbal and homeopathic preparations used for herpes virus treatment. Acta Derm Venereol 2004; 84 (3): 223–6PubMedCrossRefGoogle Scholar
  38. 38.
    Park SD, Lee SW, Chun JH, et al. Clinical features of 31 patients with systemic contact dermatitis due to the ingestion of Rhus (lacquer). Br JDermatol 2000 May; 142 (5): 937–42Google Scholar
  39. 39.
    Pfutzner W, Thomas P, Niedermeier A, et al. Systemic contact dermatitis elicited by oral intake of Balsam of Peru. Acta Derm Venereol 2003; 83 (4): 294–5PubMedCrossRefGoogle Scholar
  40. 40.
    Pfutzner W, Niedermeier A, Thomas P, et al. Systemic contact eczema against Balsam of Peru. J Dtsch Dermatol Ges 2003 Sep; 1 (9): 719–21Google Scholar
  41. 41.
    Pereira F, Hatia M, Cardoso J. Systemic contact dermatitis from diallyl disulfide. Contact Dermatitis 2002 Feb; 46 (2): 124Google Scholar
  42. 42.
    Lowther A, McCormick T, Nedorost S. Systemic contact dermatitis from propylene glycol. Dermatitis 2008 Mar-Apr; 19 (2): 105–8Google Scholar
  43. 43.
    Hill AM, Belsito DV. Systemic contact dermatitis of the eyelids caused by formaldehyde derived from aspartame? Contact Dermatitis 2003 Nov; 49 (5): 258–9Google Scholar
  44. 44.
    Watanabe T, Yoshida Y, Yamamoto O. Enteral nutrition induced systemic allergic dermatitis. Contact Dermatitis 2008 Dec; 59 (6): 374–5Google Scholar
  45. 45.
    Menne T, Weismann K. Hematogenous contact eczema following oral administration of neomycin. Hautarzt 1984; 35: 319–20PubMedGoogle Scholar
  46. 46.
    Guin JD, Fields P, Thomas KL. Baboon syndrome from i.v. aminophylline in a patient allergic to ethylendiamine. Contact Dermatitis 1999; 40: 170–1PubMedCrossRefGoogle Scholar
  47. 47.
    Isaksson M, Ljunggren B. Systemic contact dermatitis from ethylendiamine in an aminophylline preparation presenting as the baboon syndrome. Acta Derm Venereol 2003; 83: 69–70PubMedCrossRefGoogle Scholar
  48. 48.
    Proske S, Uter W, Schnuch A, et al. Severe allergic contact dermatitis with generalized spread due to bufexamac presenting as the ‘baboon’ syndrome. Dtsch Med Wochenschr 2003; 128: 545–7PubMedCrossRefGoogle Scholar
  49. 49.
    Marques C, Faria E, Machado A, et al. Allergic contact dermatitis and systemic contact dermatitis from cinchocaine. Contact Dermatitis 1995; 33: 443PubMedCrossRefGoogle Scholar
  50. 50.
    Erdmann SM, Sachs B, Merk HF. Systemic contact dermatitis from cinchocaine. Contact Dermatitis 2001; 44: 260–1PubMedGoogle Scholar
  51. 51.
    Montag G, Weber L, Gall H. Baboon-syndrom auf Allopurinol. Akt Dermatol 1996; 22: 311–3Google Scholar
  52. 52.
    Wolf R, Brenner S, Krakowski A. Intertriginous drug eruption. Acta Derm Venereol 1992; 72: 441–2PubMedGoogle Scholar
  53. 53.
    Wolf R, Orion E, Matz H. The baboon syndrome or intertriginous drug eruption: a report of eleven cases and a second look at its pathomechanism. Dermatol Online J 2003; 9: 2PubMedGoogle Scholar
  54. 54.
    Herfs H, Schirren CG, Przybilla B, et al. Baboon syndrome: a particular manifestation of hematogenous contact reaction. Hautarzt 1993; 44: 466–9PubMedGoogle Scholar
  55. 55.
    Duve S, Worret W, Hofmann H. The baboon syndrome: a manifestation of hematogenous contact-type dermatitis. Acta Derm Venereol 1994; 76: 480–1Google Scholar
  56. 56.
    Kohler LD, Schonlein K, Kautzky F, et al. Diagnosis at first glance: the baboon syndrome. Int J Dermatol 1996; 35: 502–3PubMedCrossRefGoogle Scholar
  57. 57.
    Wakelin SH, Sidhu S, Orton DI, et al. Amoxycillin-induced flexural exanthem. Clin Exp Dermatol 1999; 24: 71–3PubMedCrossRefGoogle Scholar
  58. 58.
    Kick G, Przybilla B. Delayed prick test reaction identifies amoxicillin as elicitating baboon syndrome. Contact Dermatitis 2000; 43: 366–7PubMedGoogle Scholar
  59. 59.
    Loze I, Milpied-Homsi B, Parent E, et al. Le syndrome babouin, une toxidermie particuliere: quatre observations. Nouv Dermatol 2001; 20: 624–5Google Scholar
  60. 60.
    Strub C, Bircher AJ. Exanthemwith emphasis of body flexure points 10 hours after administration of amoxicillin ‘baboon syndrome’. Schweiz Rundsch Med Prax 2002; 91: 232–4Google Scholar
  61. 61.
    Schultz ES, Diepgen TL. Clinical characteristics and the causes of the baboon syndrome. Dermatosen 1996; 44: 266–9Google Scholar
  62. 62.
    Rasmussen LP, Menne T. Systemic contact eczema in ampicillin allergy. Ugeskr Laeger 1995; 147: 1341–2Google Scholar
  63. 63.
    Helmbold P, Hegemann B, Dickert C, et al. Symmetric psychotropic and nonpigmenting fixed drug eruption due to cimetidine (so-called baboon syndrome). Dermatology 1998; 197: 402–3PubMedCrossRefGoogle Scholar
  64. 64.
    Wolf R, Elman M, Brenner S. Drug-induced ‘intertrigo’. Int J Dermatol 1993; 32: 515–6PubMedCrossRefGoogle Scholar
  65. 65.
    Garcia-Bravo B, Repiso JB, Camacho F. Systemic contact dermatitis due to deflazacort. Contact Dermatitis 2000; 43: 359–60PubMedCrossRefGoogle Scholar
  66. 66.
    Goossens C, Sass U, Song M. Baboon syndrome. Dermatology 1997; 194: 421–2PubMedCrossRefGoogle Scholar
  67. 67.
    Pfeiff B, Pullmann H. Baboon-artiges arzneiexanthem auf heparin. Deutsch Dermatologe 1991; 39: 559–60Google Scholar
  68. 68.
    Chowdhury MM, Patel GK, Inaloz HS, et al. Hydroxyurea-induced skin disease mimicking the baboon syndrome. Clin Exp Dermatol 1999; 24: 336–7PubMedCrossRefGoogle Scholar
  69. 69.
    Barbaud A, Trechot P, Granel F, et al. A baboon syndrome induced by intravenous human immunoglobulins: report of a case and immunological analysis. Dermatology 1999; 199: 258–60PubMedCrossRefGoogle Scholar
  70. 70.
    De Groot AC, Conemans JM. Systemic allergic contact dermatitis from intravesical instillation of the antitumor antibiotic mitomycin C. Contact Dermatitis 1991; 24: 201–9PubMedCrossRefGoogle Scholar
  71. 71.
    Lechner T, Grytzmann B, Baurle G. Hematogenous allergic contact dermatitis after oral administration of nystatin. Mykosen 1987; 30: 143–6PubMedGoogle Scholar
  72. 72.
    Panhans-Gross A, Gall H, Peter RU. Baboon syndrome after oral penicillin. Contact Dermatitis 1999; 41: 352–3PubMedCrossRefGoogle Scholar
  73. 73.
    Sanchez TS, Sanchez-Perez J, Aragues M, et al. Flare-up reaction of pseudoephedrine baboon syndrome positive patch test. Contact Dermatitis 2000; 42: 312–3PubMedGoogle Scholar
  74. 74.
    Sanchez-Morillas L, Reano Martos M, Rodriguez Mosquera M, et al. Baboon syndrome due to pseudoephedrine. Contact Dermatitis 2003; 48: 234PubMedCrossRefGoogle Scholar
  75. 75.
    Amichai B, Grunwald MH. Baboon syndrome following oral roxithromycin. Clin Exp Dermatol 2002; 27: 523PubMedGoogle Scholar
  76. 76.
    Gordon E. Baboon syndrome caused by Salasate. J Drugs Dermatol 2002; 1: 66PubMedGoogle Scholar
  77. 77.
    Weiss JM, Mockenhaupt M, Schopf E, et al. Reproducible drug exanthema to terbinafine with characteristic distribution of baboon syndrome. Hautarzt 2001; 52: 1104–6PubMedCrossRefGoogle Scholar
  78. 78.
    Monzon S, Del Mar Garces M, Lezaun A, et al. Ambroxol-induced systemic contact dermatitis confirmed by positive patch test. Allergol Immunopathol 2009 May-Jun; 37 (3): 167–8Google Scholar
  79. 79.
    Elmariah SB, Cheung W, Wang N, et al. Systemic drug-related intertriginous and flexural exanthema (SDRIFE). Dermatol Online J 2009 Aug 15; 15 (8): 3Google Scholar
  80. 80.
    Sans V, Jouary T, Hubiche T, et al. Baboon syndrome induced by cetuximab. Arch Dermatol 2008 Feb; 144 (2): 272–4Google Scholar
  81. 81.
    Watanabe T, Yamada N, Yoshida Y, et al. A case of symmetrical drug-related intertriginous and flexural exanthema induced by loflazepate ethyl. J Eur Acad Dermatol Venereol 2010 Mar; 24 (3): 357–8Google Scholar
  82. 82.
    Ferreira A, Mota A, Morais P, et al. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by telmisartan-hydrochlorothiazide. Cutan Ocul Toxicol 2010 Dec; 29 (4): 293–5Google Scholar
  83. 83.
    Arnold AW, Hausermann P, Bach S, et al. Recurrent flexural exanthema (SDRIFE or baboon syndrome) after administration of two different iodinated radio contrast media. Dermatology 2007; 214 (1): 89–93PubMedCrossRefGoogle Scholar
  84. 84.
    Handisurya A, Stingl G, Wöhrl S. SDRIFE (baboon syndrome) induced by penicillin. Clin Exp Dermatol 2009 Apr; 34 (3): 355–7Google Scholar
  85. 85.
    Waltermann K, Geier J, Diessenbacher P, et al. Systemic allergic contact dermatitis from intravenous piritramide. Allergy 2010 Sep; 65 (9): 1203–4Google Scholar
  86. 86.
    Akay BN, Sanli H. Symmetrical drug-related intertriginous and flexural exanthem due to oral risperidone. Pediatr Dermatol 2009 Mar-Apr; 26 (2): 214–6Google Scholar
  87. 87.
    Allain-Veyrac GG, Lebreton A, Collonnier C, et al. First case of symmetric drug-related intertriginous and flexural exanthema (SDRIFE) due to rivastigmine? Am J Clin Dermatol 2011; 12 (3): 210–3PubMedCrossRefGoogle Scholar
  88. 88.
    Daito J, Hanada K, Katoh N, et al. Symmetrical drug-related intertriginous and flexural exanthemacaused by valacyclovir. Dermatology 2009; 218 (1): 60–2PubMedCrossRefGoogle Scholar
  89. 89.
    Cunha D, Carvalho R, Santos R, et al. Systemic allergic dermatitis to epsilonaminocaproic acid. Contact Dermatitis 2009 Nov; 61 (5): 303–4Google Scholar
  90. 90.
    Thyssen JP, Maibach HI. Drug-elicited systemic allergic (contact) dermatitis: update and possible pathomechanism. Contact Dermatitis 2008; 59: 195–202PubMedCrossRefGoogle Scholar
  91. 91.
    Wolf R, Barzilai A, Davidovici B. Intertriginous lymphomatoid drug eruption. Int J Dermatol 2010 Oct; 49 (10): 1207–9Google Scholar
  92. 92.
    Guevara-Gutierrez E, Uribe-Jimenez E, Diaz-Canchola M, et al. Acute generalized exanthematous pustulosis: report of 12 cases and literature review. Int J Dermatol 2009 Mar; 48 (3): 253–8Google Scholar
  93. 93.
    Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis: analysis of 63 cases. Arch Dermatol 1991 Sep; 127 (9): 1333–8Google Scholar
  94. 94.
    Webber KA, Kos L, Holland KE, et al. Intertriginous eruption associated with chemotherapy in pediatric patients. Arch Dermatol 2007 Jan; 143 (1): 67–71Google Scholar
  95. 95.
    Valks R, Fraga J, Porras-Luque J, et al. Chemotherapy-induced eccrine squamous syringometaplasia: a distinctive eruption in patients receiving hematopoietic progenitor cells. Arch Dermatol 1997 Jul; 133 (7): 873–8Google Scholar
  96. 96.
    Hurt MA, Halvorson RD, Petr Jr FC, et al. Eccrine squamous syringometaplasia: a cutaneous sweat gland reaction in the histologic spectrum of ‘chemotherapy-associated eccrine hidradenitis’ and ‘neutrophilic eccrine hidradenitis’. Arch Dermatol 1990 Jan; 126 (1): 73–7Google Scholar
  97. 97.
    Honig PJ, Frieden IJ, Kim HJ, et al. Streptococcal intertrigo: an underrecognized condition in children. Pediatrics 2003 Dec; 112 (6 Pt 1): 1427–9Google Scholar
  98. 98.
    Iwatsuki K, Yamasaki O, Morizane S, et al. Staphylococcal cutaneous infections: invasion, evasion and aggression. J Dermatol Sci 2006 Jun; 42 (3): 203–14Google Scholar
  99. 99.
    Janniger CK, Schwartz RA, Szepietowski JC, et al. Intertrigo and common secondary skin infections. Am Fam Physician 2005 Sep 1; 72 (5): 833–8Google Scholar
  100. 100.
    Meier M, Sheth PB. Clinical spectrum and severity of psoriasis. Curr Probl Dermatol 2009; 38: 1–20PubMedCrossRefGoogle Scholar
  101. 101.
    Szigeti R, Kellermayer R. Autosomal-dominant calcium AT Pase disorders. J Invest Dermatol 2006 Nov; 126 (11): 2370–6Google Scholar
  102. 102.
    Madan V, August PJ. Exophytic plaques, blisters,and mouth ulcers: pemphigus vegetans (PV), Neumann type. Arch Dermatol 2009 Jun; 145 (6): 715–20Google Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Department of Dermatology, Sunnybrook HospitalUniversity of TorontoTorontoCanada
  2. 2.Sunnybrook Dermatology ClinicTorontoCanada

Personalised recommendations